PMID- 38496849
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240319
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 10
IP  - 6
DP  - 2024 Mar 30
TI  - Mechanisms of action of Shizhenqing granules for eczema treatment: Network 
      pharmacology analysis and experimental validation.
PG  - e27603
LID - 10.1016/j.heliyon.2024.e27603 [doi]
LID - e27603
AB  - BACKGROUND: Jiuwan decoction has been used to treat chronic eczema since the Qing 
      Dynasty. According to clinical experience, Shizhenqing granules (SZQG), derived 
      from the Jiuwan decoction, exert beneficial clinical effects on acute eczema and 
      reduce recurrence. Therefore, we elucidated the underlying mechanisms of SZQG 
      through network pharmacology, molecular docking, and experimental validation. 
      METHODS: The main chemical components of SZQG were identified by 
      ultra-high-performance liquid chromatography-tandem mass spectrometry 
      (UHPLC-MS/MS). And the targets of SZQG against eczema were screened out through 
      online databases. Then, the regulatory network map of the "herbal 
      compound-potential target" and the target protein-protein interaction (PPI) 
      network was constructed. The Gene Ontology (GO) analysis and the Kyoto 
      Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were 
      conducted using by R language. Additionally, the interaction between the active 
      compounds and the targets was verified by molecular docking technology. Finally, 
      an experiment in vivo was used to verify the effect and mechanism of SZQG on 
      eczema. RESULTS: Using UHPLC-MS/MS, 158 main chemical compounds of SZQG were 
      identified, and 72 compounds were selected according to the criteria for further 
      analysis. All 237 potential targets of SZQG in eczema were explored using 
      multiple online databases. The network with 14 core targets was screened out, 
      including STAT3, RELA, TNF, JUN, MAPK3, IL-6, PIK3CA, STAT1, MAPK14, MAPK1, IL-4, 
      NFKBIA, IL1B, and MYC. KEGG analyses indicated that the therapeutic effects of 
      SZQG on eczema were predominantly associated with cytokine-cytokine receptor 
      interaction, TNF, MAPK, NF-kappaB, toll-like receptor, T cell receptor, and Th1 and 
      Th2 cell differentiation signaling pathways. Furthermore, the good affinity 
      between the core compounds and core targets was verified by molecular docking 
      technology, particularly for RELA and MAPK. Animal experiments revealed that SZQG 
      downregulated MAPK14, RELA, T-bet, and GATA3 mRNA expression, reduced 
      immunoglobulin E (IgE) and interleukin-4 (IL-4) serum concentrations, and 
      improved eczema-like lesions in model rats. CONCLUSION: This study identified 
      potential targets and signaling pathways of SZQG in the treatment of eczema, 
      whereby RELA and MAPK14 may constitute the main therapeutic targets of SZQG in 
      cytokine regulation and reduction of inflammatory responses.
CI  - (c) 2024 The Authors.
FAU - Zhang, Hairong
AU  - Zhang H
AD  - Department of Integrated Chinese and Western Medicine, Yantai Yuhuangding 
      Hospital, Yantai, 264000, Shandong, China.
FAU - Li, Zhenbo
AU  - Li Z
AD  - Oregon College of Oriental Medicine, Portland, OR, 97209, USA.
FAU - Sun, Yike
AU  - Sun Y
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
      Beijing, 102488, China.
FAU - Li, Wenna
AU  - Li W
AD  - Department of Acupuncture and Minimally Invasive Oncology, Beijing University of 
      Chinese Medicine Third Affiliated Hospital, Beijing, 100029, China.
FAU - Sun, Xiao
AU  - Sun X
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
      Beijing, 102488, China.
FAU - Zhang, Yapeng
AU  - Zhang Y
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
      Beijing, 102488, China.
FAU - Liu, Leilei
AU  - Liu L
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
      Beijing, 102488, China.
FAU - Ma, Shuran
AU  - Ma S
AD  - School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, 
      Beijing, 102488, China.
LA  - eng
PT  - Journal Article
DEP - 20240308
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10944262
OTO - NOTNLM
OT  - Eczema
OT  - Inflammatory response
OT  - Molecular docking
OT  - Network pharmacology
OT  - Shizhenqing granules
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/03/18 06:43
MHDA- 2024/03/18 06:44
PMCR- 2024/03/08
CRDT- 2024/03/18 04:43
PHST- 2023/05/04 00:00 [received]
PHST- 2024/03/03 00:00 [revised]
PHST- 2024/03/04 00:00 [accepted]
PHST- 2024/03/18 06:44 [medline]
PHST- 2024/03/18 06:43 [pubmed]
PHST- 2024/03/18 04:43 [entrez]
PHST- 2024/03/08 00:00 [pmc-release]
AID - S2405-8440(24)03634-X [pii]
AID - e27603 [pii]
AID - 10.1016/j.heliyon.2024.e27603 [doi]
PST - epublish
SO  - Heliyon. 2024 Mar 8;10(6):e27603. doi: 10.1016/j.heliyon.2024.e27603. eCollection 
      2024 Mar 30.